M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 8.5 PLN -0.7% Market Closed
Market Cap: 137.4m PLN
Have any thoughts about
Mabion SA?
Write Note

Mabion SA
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mabion SA
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
M
Mabion SA
WSE:MAB
Other Operating Expenses
-zł574k
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Other Operating Expenses
-zł6.4m
CAGR 3-Years
-84%
CAGR 5-Years
3%
CAGR 10-Years
-18%
G
Genomed SA
WSE:GEN
Other Operating Expenses
-zł752k
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Other Operating Expenses
zł13.7m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
14%
U
Urteste SA
WSE:URT
Other Operating Expenses
-zł1.9m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Other Operating Expenses
-zł502k
CAGR 3-Years
N/A
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Mabion SA
Glance View

Market Cap
137.4m PLN
Industry
Biotechnology

Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

MAB Intrinsic Value
13.69 PLN
Undervaluation 38%
Intrinsic Value
Price
M

See Also

What is Mabion SA's Other Operating Expenses?
Other Operating Expenses
-574k PLN

Based on the financial report for Sep 30, 2024, Mabion SA's Other Operating Expenses amounts to -574k PLN.

What is Mabion SA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 3Y
57%

The average annual Other Operating Expenses growth rates for Mabion SA have been 57% over the past three years .

Back to Top